Replies to post #250704 on Biotech Values

[bladerunner1717]

Mufaso.

Do you think GRTS has a an even remote chance in the Covid vaccine space?

Bladerunner

[DewDiligence]

RAPT—(-34%)—ends_clinical_programs_in atopic dermatitis and asthma:

https://finance.yahoo.com/news/rapt-therapeutics-reports-first-quarter-120000252.html

The Company also announced today that it has decided to close and unblind both its Phase 2b clinical trial of zelnecirnon (RPT193) in atopic dermatitis (“AD”) and its Phase 2a trial of zelnecirnon in asthma. Both clinical trials were placed on clinical hold by the FDA in February 2024 based on a serious adverse event of liver failure requiring transplant in one patient in the AD trial.